Cite
Costa Neves M, Giakoustidis A, Stamp G, et al. Extended Survival after Complete Pathological Response in Metastatic Pancreatic Ductal Adenocarcinoma Following Induction Chemotherapy, Chemoradiotherapy, and a Novel Immunotherapy Agent, IMM-101. Cureus. 2015;7(12):e435doi: 10.7759/cureus.435.
Costa Neves, M., Giakoustidis, A., Stamp, G., Gaya, A., & Mudan, S. (2015). Extended Survival after Complete Pathological Response in Metastatic Pancreatic Ductal Adenocarcinoma Following Induction Chemotherapy, Chemoradiotherapy, and a Novel Immunotherapy Agent, IMM-101. Cureus, 7(12), e435. https://doi.org/10.7759/cureus.435
Costa Neves, Mafalda, et al. "Extended Survival after Complete Pathological Response in Metastatic Pancreatic Ductal Adenocarcinoma Following Induction Chemotherapy, Chemoradiotherapy, and a Novel Immunotherapy Agent, IMM-101." Cureus vol. 7,12 (2015): e435. doi: https://doi.org/10.7759/cureus.435
Costa Neves M, Giakoustidis A, Stamp G, Gaya A, Mudan S. Extended Survival after Complete Pathological Response in Metastatic Pancreatic Ductal Adenocarcinoma Following Induction Chemotherapy, Chemoradiotherapy, and a Novel Immunotherapy Agent, IMM-101. Cureus. 2015 Dec 26;7(12):e435. doi: 10.7759/cureus.435. PMID: 26870619; PMCID: PMC4731256.
Copy
Download .nbib